Form 4: Lexicon Pharmaceuticals SVP, CFO Scott Coiante Acquires 230,000 Stock Options

Scott M. Coiante, SVP and CFO of Lexicon Pharmaceuticals, acquired 230,000 stock options on January 2, 2025, according to a Form 4 filing with the SEC.

Summary

• On January 2, 2025, Scott M. Coiante, the SVP and Chief Financial Officer of Lexicon Pharmaceuticals, acquired 230,000 stock options.
• The options have an exercise price of $0.7385.
• The options vest with respect to 25% of the shares on the first anniversary of the grant date, and then 1/48th per month for each month of service thereafter.
• The options expire on January 2, 2035.
• Following the transaction, Mr. Coiante directly owns 230,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which can be seen as a standard part of executive compensation.

Positives

• The acquisition of stock options by a high-ranking officer can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a company officer can have a minor positive impact on shareholder sentiment, as it aligns the officer's interests with those of the shareholders.

Key Dates